Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

Broad Agency Announcement for the Advanced Development of Medical Countermeasures for Pandemic Influenza

Solicitation Number: BAA-13-100-SOL-00019
Agency: Department of Health and Human Services
Office: Office of the Secretary
Location: Acquisitions Management, Contracts, & Grants (AMCG)
  • Print

Note:

There have been modifications to this notice. To view the most recent modification/amendment, click here
:
BAA-13-100-SOL-00019
:
Solicitation
:
Added: Jul 16, 2013 1:48 pm Modified: Sep 25, 2013 4:00 pmTrack Changes
***UPDATE to BAA: References to ORCA and CCR are changed to System for Award Management, www.sam.gov. The Report of Government-owned, Contractor-held Property is available at http://oamp.od.nih.gov/DGS/FORMS/Govt-Owned-Prop.pdf.

A Broad Agency Announcement (BAA) will be issued that sets forth advanced development areas of interest for the Influenza Division of the Office of the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.

BARDA is the lead Federal agency for the advanced development of medical countermeasures (MCM) to protect the United States against public health emergency threats, including chemical, biological, radiological and nuclear agents, emerging infectious diseases, and pandemic influenza.


The Pandemic and All Hazard Preparedness Act, Pub. L. No. 109-417, 42 U.S.C. § 241 et seq. (PAHPA; http://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf) and The Pandemic and All Hazard Preparedness Reauthorization Act, Pub. L. No. 113-5, (PAHPRA; http://www.gpo.gov/fdsys/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf) direct BARDA to promote (i) innovations in technologies that may assist MCM advanced research and development, (ii) research and development of tools, devices, and technologies, and (iii) research to promote strategic initiatives, such as rapid diagnostics, broad spectrum antimicrobials, and vaccine manufacturing technologies.


BARDA's Influenza Division seeks the advanced research and development of MCMs to protect the civilian population of the United States against pandemic influenza, and anticipates that research and development activities awarded under the BAA will serve to advance the knowledge and scientific understanding of candidate MCMs toward licensure or approval by the Food and Drug Administration.


The priorities of the BARDA Influenza Division are closely aligned with the National Strategy for Pandemic Influenza (November 2005), the National Pandemic Influenza Implementation Plan (May 2005), The Public Health Emergency Medical Countermeasures Enterprise Review (August 2010), the President's Council of Advisors on Science and Technology report on influenza vaccine manufacturing (August 2010), and the BARDA Strategic Plan 2011-2016 (October 2011).


Influenza Areas of Interest


The BAA will seek white papers that focus on one or more of the following areas of interest, which will be further described in Part I of the BAA.

1. Personal Protective Equipment (Masks and Respirators) for Influenza Infection & All-
    Hazards
2. Full-Featured Continuous Ventilators for Influenza Infection and All-Hazards
3. Clinical Influenza Test Systems and Diagnostic Tools
4. Influenza Therapeutics
5. Influenza Vaccines
6. Influenza Vaccine Manufacturing Improvement


The BAA will be issued under sections 6.102(d)(2) and 35.016 of the Federal Acquisition Regulation, and submissions selected for award will result from full and open competition in compliance with The Competition in Contracting Act of 1984, Pub. L. No. 98-369, as amended.


This synopsis is not a BAA; the BAA is anticipated to be posted on or about July 31, 2013. The BAA's open period will be identified in the BAA itself. The BAA will be open to all responsible sources regardless of business size. Multiple awards may be made under the BAA.


Contact Information:


Comments on this synopsis should reference BAA-13-100-SOL-00019 and be submitted to FLU-BAA@hhs.gov.

Added: Apr 02, 2014 2:51 pm
*** UPDATE to BAA:  Amendment No. 0002 is issued.
Please consult the list of document viewers if you cannot open a file.

Solicitation 1

Type:
Solicitation
Posted Date:
July 31, 2013
Description: Broad Agency Announcement for the Advanced Development of Medical Countermeasures for Pandemic Influenza

Solicitation 2

Type:
Solicitation
Posted Date:
August 9, 2013
Description: Broad Agency Announcement for the Advanced Development of Medical Countermeasures for Pandemic Influenza

Amendment 1

Type:
Mod/Amendment
Posted Date:
October 18, 2013
Description: Amendment #01 to BAA-13-100-SOL-00019

The First Cut-Off Date For Quad Charts And White Papers Is Extended From October 30, 2013 To November 15, 2013.

Amendment 2

Type:
Mod/Amendment
Posted Date:
April 2, 2014
Description: Amendment No. 0002 (i) authorizes the use of Other Transaction agreements for all Areas of Interest in the BAA, (ii) extends the period of the BAA by one year, and (iii) issues two new subsections to Area of Interest No. 4, Influenza Therapeutics.
:
Office of the Assistant Secretary for Preparedness & Response (ASPR)
Department of Health and Human Services
330 Independence Ave. SW
G640
Washington, District of Columbia 20201
United States
:
Tasha A. McMillian,
Contracting Officer
Phone: 202-205-1502
:
Kevin Nilles,
Contracting Officer
Phone: 202-245-0969